Hims & Hers rises after plan to sell Eli Lilly's weight loss drug on its platform
Shares of telehealth firm Hims & Hers HIMS.N rise 11.2% to $32.88
HIMS says it plans to sell Eli Lilly's LLY.N weight-loss and diabetes drug on its platform
Co says it will offer both branded versions of Lilly's tirzepatide, the active ingredient in weight loss drug Zepbound and diabetes medicine Mounjaro, as well as generics of Novo Nordisk's NOVOb.CO diabetes drug, liraglutide
HIMS joins its peers such as Teladoc TDOC.N and LifeMD LFMD.O to offer Lilly's Zepbound ahead of restrictions on selling copies known as compounded drugs
Including session's moves, HIMS stock up 36.4% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Tradingkey






